Tyvaso (treprostinil) NDC 66302-206

NDC codes

FDA NDC Directory

Product NDC (as listed)66302-206Labeler and product segments. Claims need a package NDC.

Product NDC at billing width66302-0206Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
66302-206-01	66302020601	1 BOX in 1 KIT (66302-206-01) / 28 AMPULE in 1 BOX / 2.9 mL in 1 AMPULEMarketed from Aug 14, 2009
66302-206-02	66302020602	1 BOX in 1 KIT (66302-206-02) / 28 AMPULE in 1 BOX / 2.9 mL in 1 AMPULEMarketed from Aug 14, 2009
66302-206-03	66302020603	4 AMPULE in 1 BOX (66302-206-03) / 2.9 mL in 1 AMPULEMarketed from Aug 14, 2009
66302-206-04	66302020604	1 BOX in 1 KIT (66302-206-04) / 4 AMPULE in 1 BOX / 2.9 mL in 1 AMPULEMarketed from Aug 14, 2009

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tyvaso
Generic name (nonproprietary): treprostinil
Active ingredients: Treprostinil — 1.74 mg/2.9mL
Dosage form: Inhalant
Route: Oral
Labeler: United Therapeutics Corporation
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022387
Marketing start: Aug 14, 2009
Listing expires: Dec 31, 2027
Other FDA classes: Prostaglandins I (Chemical structure)Vasodilation (Physiologic effect)
Identifiers: Product ID 66302-206_78a0b514-481a-4ea9-8ec6-8b60acdf2158SPL ID 78a0b514-481a-4ea9-8ec6-8b60acdf2158SPL set ID cbc31ab1-a80f-4b50-a3b1-39910b0fb609RxCUI 857795, 857799UNII RUM6K67ESG
Pharmacologic class: Prostacycline Vasodilator

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N466302020601 followed by a unit qualifier and the quantity

Package 66302-0206-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 14, 2026.

Indications (excerpt from the label)

Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)